Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 6:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cushing's Disease Clear all
Completed No phase listed Observational Accepts healthy volunteers

Cognition, Steroids, and Imaging in Cushings Disease

NCT00081341
View directory record Official record
Conditions
Cushing Syndrome
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
9 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2002
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 14, 2010 · Synced Jul 23, 2026, 6:07 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing Disease

NCT05971758
View directory record Official record
Conditions
Cushing Disease
Interventions
Fimepinostat
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 23, 2026, 6:07 AM EDT
Recruiting Phase 2 Interventional

Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease

NCT03774446
View directory record Official record
Conditions
Cushing Disease
Interventions
Seliciclib
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Jul 23, 2026, 6:07 AM EDT
Recruiting Early Phase 1 Interventional

FET PET/CT Imaging To Localize Pituitary Adenomas In Cushing Disease

NCT07460232
View directory record Official record
Conditions
Cushing Disease, Pituitary Adenoma
Interventions
Fluoro-O-(2) fluoroethyl-L-tyrosine (FET) PET
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Jul 23, 2026, 6:07 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of LCI699 in Cushing's Disease Patients

NCT01331239
View directory record Official record
Conditions
Cushings Disease, Cushing Disease
Interventions
LCI699
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
4
States / cities
Chicago, Illinois • Boston, Massachusetts • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2021 · Synced Jul 23, 2026, 6:07 AM EDT
Not listed No phase listed Observational

Study of Depression, Peptides, and Steroids in Cushing's Syndrome

NCT00004334
View directory record Official record
Conditions
Cushing's Syndrome
Interventions
Not listed
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
20 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1994
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 23, 2026, 6:07 AM EDT
Terminated Phase 2 Interventional Results available

Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease

NCT01915303
View directory record Official record
Conditions
Cushings Disease
Interventions
Pasireotide with or without cabergoline
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
2
States / cities
Birmingham, Alabama • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 17, 2020 · Synced Jul 23, 2026, 6:07 AM EDT
Completed No phase listed Observational

Study of Cushing's Syndrome Not Related to ACTH Production

NCT00006278
View directory record Official record
Conditions
Cushing's Syndrome, Healthy
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Not listed
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 23, 2026, 6:07 AM EDT
Completed Phase 4 Interventional Results available

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

NCT01794793
View directory record Official record
Conditions
Cushing's Disease, Acromegaly, Neuroendocrine Tumors, Pituitary Tumors, Ectopic ACTH Secreting (EAS) Tumors, Dumping Syndrome, Prostate Cancer, Melanoma Negative for bRAF, Melanoma Negative for nRAS
Interventions
Pasireotide, Cabergoline, Pasireotide LAR
Drug
Lead sponsor
RECORDATI GROUP
Industry
Eligibility
18 Years and older
Enrollment
337 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
7
States / cities
La Jolla, California • Los Angeles, California • Stanford, California + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2024 · Synced Jul 23, 2026, 6:07 AM EDT
Completed Phase 3 Interventional Results available

An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease.

NCT01582061
View directory record Official record
Conditions
Cushing's Disease
Interventions
Pasireotide sub-cutaneous
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
17
States / cities
Peoria, Arizona • Phoenix, Arizona • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Jul 23, 2026, 6:07 AM EDT
Completed Phase 3 Interventional Results available

An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome

NCT00936741
View directory record Official record
Conditions
Cushing's Syndrome
Interventions
mifepristone
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
15
States / cities
Birmingham, Alabama • Escondido, California • Stanford, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2014 · Synced Jul 23, 2026, 6:07 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Dose Response Relationship for Single Doses of Corticotropin Releasing Hormone (CRH) in Normal Volunteers and in Patients With Adrenal Insufficiency

NCT00001180
View directory record Official record
Conditions
Adrenal Gland Hyperfunction, Adrenal Gland Hypofunction, Cushing's Syndrome, Healthy
Interventions
Ovine Corticotropin-Releasing Hormone (oCRH)
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Not listed
Enrollment
2,250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1982 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 23, 2026, 6:07 AM EDT
Terminated Phase 2 Interventional Results available

Treatment of Cushing's Disease With R-roscovitine

NCT02160730
View directory record Official record
Conditions
Cushings Disease
Interventions
R-roscovitine
Drug
Lead sponsor
Shlomo Melmed, MD
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Jul 23, 2026, 6:07 AM EDT
Completed Phase 2 Interventional

SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome

NCT05307328
View directory record Official record
Conditions
Cushing's Syndrome I, Cushing Disease Due to Increased ACTH Secretion, Cortisol Excess, Cortisol; Hypersecretion, Cortisol Overproduction, Ectopic ACTH Secretion
Interventions
SPI-62, Placebo
Drug
Lead sponsor
Sparrow Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
8
States / cities
Phoenix, Arizona • Fort Myers, Florida • Rochester, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Jul 23, 2026, 6:07 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome

NCT05804669
View directory record Official record
Conditions
Cushing Syndrome, Cushing Disease, Ectopic ACTH Syndrome
Interventions
atumelnant
Drug
Lead sponsor
Crinetics Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jul 23, 2026, 6:07 AM EDT
Terminated No phase listed Observational

A Study to Confirm Recurrent or Persistent Cushing's Syndrome in Patients With Signs or Symptoms of Hypercortisolemia

NCT00796783
View directory record Official record
Conditions
Cushing's Syndrome
Interventions
Cushing's syndrome confirmation
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
3
States / cities
Escondido, California • Hollywood, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 19, 2014 · Synced Jul 23, 2026, 6:07 AM EDT
Completed Phase 3 Interventional Results available

Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome

NCT01371565
View directory record Official record
Conditions
Cushing's Disease, Cushing's Syndrome
Interventions
Mifepristone
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
5
States / cities
Hollywood, Florida • Baltimore, Maryland • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2014 · Synced Jul 23, 2026, 6:07 AM EDT
Terminated Phase 2 Interventional Results available

Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) Secretion

NCT00422201
View directory record Official record
Conditions
Cushing's Syndrome
Interventions
Mifepristone
Drug
Lead sponsor
HRA Pharma
Industry
Eligibility
18 Years to 85 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 10, 2019 · Synced Jul 23, 2026, 6:07 AM EDT
Recruiting No phase listed Observational

Evaluation of Intraoperative Contrast Enhanced Ultrasound for the Identification of Pituitary Adenoma in Cushing's Disease Compared to Other Pituitary Tumors

NCT07335315
View directory record Official record
Conditions
Pituitary Adenoma, Cushing Disease
Interventions
Contrast enhanced pituitary magnetic resonance imaging (MRI), Contrast enhanced ultrasound, Non-Contrast Ultrasound
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
Not listed
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Jul 23, 2026, 6:07 AM EDT
Completed Phase 2 Interventional

A Study to Assess SOM230 in Patients With Pituitary Cushing's Disease

NCT00088608
View directory record Official record
Conditions
Cushing's Syndrome
Interventions
SOM230 s.c.
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
5
States / cities
Los Angeles, California • Boston, Massachusetts • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2016 · Synced Jul 23, 2026, 6:07 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate CORT125134 in Participants With Cushing's Syndrome

NCT02804750
View directory record Official record
Conditions
Cushing's Syndrome
Interventions
CORT125134
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
12
States / cities
Laguna Hills, California • Aurora, Colorado • Fort Lauderdale, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2019 · Synced Jul 23, 2026, 6:07 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome

NCT00569582
View directory record Official record
Conditions
Cushing's Syndrome
Interventions
mifepristone
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
17
States / cities
Birmingham, Alabama • Escondido, California • Stanford, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2013 · Synced Jul 23, 2026, 6:07 AM EDT
Completed No phase listed Observational

Adolescence, Puberty, and Emotion Regulation

NCT00016731
View directory record Official record
Conditions
Mood Disorder, Neurobehavioral Manifestation, Healthy
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
8 Years to 55 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Jul 23, 2026, 6:07 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

An Investigation of Pituitary Tumors and Related Hypothalmic Disorders

NCT00001595
View directory record Official record
Conditions
Panhypopituitarism, Gigantism/Acromegaly, Prolactinoma, Cushing Disease
Interventions
Tissue specimen collection, MRI
Procedure
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
2 Years to 70 Years
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1997
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Jul 23, 2026, 6:07 AM EDT